Activity

Filter

Cancel
Date Panel Item Activity
6 actions
Genomic screening in children: BabyScreen+ v0.46 DMD Zornitza Stark Tag clinical trial tag was added to gene: DMD.
Tag neurological tag was added to gene: DMD.
Genomic screening in children: BabyScreen+ v0.38 DMD Zornitza Stark Marked gene: DMD as ready
Genomic screening in children: BabyScreen+ v0.38 DMD Zornitza Stark Gene: dmd has been classified as Green List (High Evidence).
Genomic screening in children: BabyScreen+ v0.38 DMD Zornitza Stark Classified gene: DMD as Green List (high evidence)
Genomic screening in children: BabyScreen+ v0.38 DMD Zornitza Stark Gene: dmd has been classified as Green List (High Evidence).
Genomic screening in children: BabyScreen+ v0.37 DMD Zornitza Stark gene: DMD was added
gene: DMD was added to Genomic screening in children: BabyScreen+. Sources: Expert Review
Mode of inheritance for gene: DMD was set to X-LINKED: hemizygous mutation in males, biallelic mutations in females
Phenotypes for gene: DMD were set to Duchenne muscular dystrophy MIM#310200
Review for gene: DMD was set to GREEN
Added comment: Well established gene-disease association. Milder phenotypes such as BMD and DCM are also associated with variants in this gene. Females typically at risk for cardiac disease only.

Onset in early childhood.

Treatment: Eteplirsen, Casimersen and Golodirsen for exon skipping 51, 45 and 53, respectively. Vitolarsen has also been approved for exon 53 skipping.

Pilots are underway to assess NBS for DMD, including one planned in NSW. Most programs are based on raised CK levels.

Discussed with Neurology: include.
Sources: Expert Review